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Abstract
Background: Platelets are anuclear cell fragments derived from bone marrow megakaryocytes that safeguard vascular
integrity, but may also cause pathological vessel occlusion. Reorganizations of the platelet cytoskeleton and agonist-
induced intracellular Ca2+-mobilization are crucial for platelet hemostatic function. EF-hand domain containing 2 (EFhd2,
Swiprosin-1) is a Ca2+-binding cytoskeletal adaptor protein involved in actin remodeling in different cell types, but its
function in platelets is unknown.
Objective: Based on the described functions of EFhd2 in immune cells, we tested the hypothesis that EFhd2 is a crucial
adaptor protein for platelet function acting as a regulator of Ca2+-mobilization and cytoskeletal rearrangements.
Methods and Results: We generated EFhd2-deficient mice and analyzed their platelets in vitro and in vivo. Efhd2-/- mice
displayed normal platelet count and size, exhibited an unaltered in vivo life span and showed normal Ca2+-mobilization and
activation/aggregation responses to classic agonists. Interestingly, upon stimulation of the immunoreceptor tyrosine-based
activation motif-coupled receptor glycoprotein (GP) VI, Efhd2-/- platelets showed a slightly increased coagulant activity.
Furthermore, absence of EFhd2 had no significant impact on integrin-mediated clot retraction, actomyosin rearrangements
and spreading of activated platelets on fibrinogen. In vivo EFhd2-deficiency resulted in unaltered hemostatic function and
unaffected arterial thrombus formation.
Conclusion: These results show that EFhd2 is not essential for platelet function in mice indicating that other cytoskeletal
adaptors may functionally compensate its loss.
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Introduction
Platelets are small anucleated cell fragments derived from the
cytoplasm of bone marrow megakaryocytes (MKs). At sites of
vascular injury, platelets adhere and aggregate on the exposed
subendothelial extracellular matrix (ECM) and thereby form a
plug that seals the wound. This process is essential for normal
hemostasis, but in diseased vessels it may lead to pathological
thrombus formation and infarction of vital organs [1,2]. Platelet
activation on the injured vessel wall is induced by multiple
signaling pathways and leads to extensive cytoskeletal rearrange-
ments that are crucial for conversion from discoid to spheric
shape, granule secretion, spreading and, at later time points clot
retraction [3]. Many of these processes are controlled by proteins
of the Rho family of small GTPases, like RhoA, Rac1, and Cdc42
and their downstream effector molecules such as the Wiskott-
Aldrich syndrome proteins (WASPs), formins and p21-activated
kinases (PAKs) [4]. In addition, cytoskeletal adaptor proteins such
as talin1 and kindlin-3 are crucial for platelet function by linking
the actin cytoskeleton to integrins thereby enabling their shift from
low to high affinity for their ligands and thus stable platelet
adhesion and aggregation [5,6].
Elevation of cytosolic Ca2+ is a central step during platelet
activation. It is induced through the release of Ca2+ from
intracellular stores and subsequent Ca2+ entry through the plasma
membrane, a process called store-operated Ca2+ entry (SOCE),
which represents the major influx pathway of extracellular Ca2+ in
platelets [7]. This process is regulated by the endoplasmic
reticulum membrane-bound protein stromal interaction molecule
1 (STIM1) that senses Ca2+ depletion in intracellular stores via its
EF hand motifs and Orai1, the major SOCE channel in the
plasma membrane [7]. Finally, increased intracellular Ca2+ leads
to the activation of the cytosolic EF-hand domain containing Ca2+
sensor CalDAG-GEFI [8] that links Ca2+ mobilization to signaling
pathways regulating thromboxane A2 (TxA2) generation, integrin
activation and granule release [9], thereby promoting platelet
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spreading [10], clot retraction [11], coagulant activity [12,13], and
platelet aggregation [14].
EF-hand domain containing 2 (EFhd2, also called Swiprosin-1)
belongs to the EF-hand superfamily of Ca2+-binding proteins [15],
consisting of an N-terminal region of low complexity with an
alanine stretch, a functional SH3 binding motif [16], two
functional EF hands [17] and a C-terminal coiled-coil domain
[15], the latter capable of mediating self-oligomerization in a
Ca2+-dependent manner [18]. Constitutive EFhd2-deficient mice
revealed a function of this cytoskeletal adaptor protein in the
negative regulation of germinal center-dependent humoral immu-
nity [19]. Besides B cells and other hematopoietic cells [15],
EFhd2 is predominantly expressed in the brain [20] and has been
associated with tau-mediated neurodegeneration [21]. In addition,
EFhd2 negatively regulates axonal transport in hippocampal
neurons by inhibiting kinesin mediated microtubule gliding [22].
In natural killer (NK)-like cells, EFhd2 was found in the
cytoskeleton fraction together with actin and actin-binding
proteins such as a-actinin and filamin [23] and it was shown that
EFhd2 directly binds to F-actin thereby modulating F-actin
bundling and cell spreading in a Ca2+-dependent manner [18].
In line with this, EFhd2 co-localizes with F-actin and regulates
actin remodeling in a human mast cell line [24,25] and modulates
lamellipodial dynamics by regulating the accessibility of F-actin to
cofilin in melanoma cells [26]. A study characterizing sepsis-
induced changes in the MK–platelet transcriptional axis revealed
that EFhd2 mRNA was highly up-regulated in mice after
induction of sepsis by the cecal ligation and puncture model
[27]. Furthermore, a proteomic approach identified a minor up-
regulation of EFhd2 expression in rat and human platelets upon
stimulation with thrombin [28]. However, due to the lack of an
appropriate animal model, the role of EFhd2 in platelet function
has remained elusive.
Here we show that constitutive Efhd2-/- mice display unaltered
platelet production and the function of the cells was indistinguish-
able from WT controls in a wide range of in vitro and in vivo




Efhd2-/- mice [19] and their wild-type littermates were on a
C57Bl/6 background. Mice used for the experiments were
between 6 and 12 weeks of age if not indicated differently.
Animal studies were approved by the district government of Lower
Franconia (Bezirksregierung Unterfranken).
Chemicals and reagents
Midazolam (Roche Pharma AG), fentanyl (Janssen-Cilag
GmbH) and the antagonists atipamezol (Pfizer), flumazenil and
naloxone (both from Delta Select GmbH) were used according to
the regulation of the local authorities. Thrombin (Roche
Diagnostics), ADP, low-molecular-weight heparin and human
fibrinogen (Sigma-Aldrich), U46619 (Enzo Life Sciences), collagen
(Kollagenreagent Horm; Nycomed), apyrase Type III (Sigma-
Aldrich), Fura-2 AM and Pluronic F-127 (Molecular Probes) were
purchased, collagen-related peptide (CRP) was generated as
described [29]. Antibodies against Rac1 (Millipore), actin
(Sigma-Aldrich), tubulin (Millipore), mDia1 (Abcam), PAK1/2/
3, phosphor-PAK1/2 (423/402), Syk, phosphor-Syk (Y519/520),
cofilin, phospho-cofilin (Ser3) as well goat anti-rabbit IgG-HRP
(all from Cell Signaling) were purchased. The antibody against the
activated form of integrin aIIbb3 ( JON/A-PE) was from Emfret
Analytics (Eibelstadt, Germany). Annexin-V was generously
provided by Jonathan F Tait, University of Washington Medical
Center and conjugated to DyLight 488 by standard methods. All
other antibodies were generated and modified in our laboratories
as previously described [30,31].
Platelet preparation
Mice were bled under isofluran anesthesia from the retro-orbital
plexus. Blood was collected in a tube containing 20 U/mL
heparin, and platelet-rich plasma (prp) was obtained by two cycles
of centrifugation at 300 g for 6 minutes at room temperature (RT).
For preparation of washed platelets, prp was washed twice at
800 g for 5 minutes at RT and the pellet was resuspended in
Tyrodes-HEPES in the presence of prostacyclin (0.1 mg/mL) and
apyrase (0.02 U/mL). Platelets were then resuspended in Tyrodes-
HEPES buffer containing 2 mmol/L CaCl2 and 0.02 U/mL
apyrase.
Platelet life span
To determine platelet life span in vivo, mice were injected
intravenously with DyLight-488 conjugated anti-GPIX Ig deriv-
ative (0.5 mg/g body weight). At 1 h after injection (day 0), as well
as at the other indicated time points, 50 ml blood were collected
and the percentage of GPIX-positive platelets was determined by
flow cytometry.
Platelet spreading
Cover slips were coated with 100 mg/mL human fibrinogen and
blocked with 1% BSA/PBS. After rinsing with Tyrodes-HEPES
buffer, washed platelets (100 mL with 0.036106 platelets/mL) were
activated with thrombin (0.01 U/mL) and immediately placed on
the coated cover slips. At indicated time points, the cover slips
were rinsed again and platelets were visualized with a Zeiss
Axiovert 200 inverted microscope (100x/1.4 oil objective). Digital
images were recorded using a CoolSNAP-EZ camera (Visitron)
and analyzed off-line using Metavue software (Molecular Devises).
Four different stages of platelet spreading were evaluated: stage 1 -
roundish; stage 2 - filopodia only; stage 3 - filopodia and
lamellipodia; stage 4 - fully spread.
Platelet aggregometry
Light transmission was measured on a Fibrintimer 4 channel
aggregometer (APACT Laborgera¨te und Analysensysteme) using
prp (for ADP) or washed platelets (for all other agonists - 160 mL
with 1.566105 platelets/mL). Measurements in washed platelets
were performed in the presence of 70 mg/mL fibrinogen, except
for thrombin.
Flow cytometry
Washed blood was activated with agonists at the indicated
concentrations, stained with fluorophore-conjugated monoclonal
antibodies at saturating concentrations for 10 minutes at 37uC and
analyzed on a FACSCalibur (BD Biosciences). For determination
of phosphatidylserine exposure, washed platelets (0.056106/mL)
were stimulated with the indicated agonists in the presence of
Annexin-V-DyLight 488 for 15 minutes at 37uC. The reaction was
stopped by addition of 500 ml Tyrodes-HEPES containing 3 mM
Ca2+ and samples were directly analyzed on a FACSCalibur (BD
Biosciences).
Clot retraction
Clot retraction studies were performed at 37uC in an
aggregometer tube containing diluted prp (36105 platelets/mL),
Function of EFhd2 in Murine Platelets
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thrombin (4 U/mL), and CaCl2 (20 mmol/L). Clot retraction was
recorded with a digital camera over a time span of 4 hours after
activation.
Western blot analysis
Washed platelets or splenocytes were lysed in lysis buffer
(300 mM NaCl, 20 mM TRIS, 2 mM EGTA, 2 mM EDTA,
2 mM Na3VO4, 10 mM NaF, pH 7.5, supplemented with
protease inhibitor cocktail (Sigma-Aldrich) containing 1% Igepal
CA-630 for 20 minutes at 4uC, centrifuged at 14,000 rpm for
10 minutes and the supernatants were collected. 46Laemmli
sample buffer was added, and the samples boiled at 95uC for
5 min. Next, samples were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing
conditons and blotted onto a polyvinylidene difluoride (PVDF)
membrane. The membranes were blocked for 1 hour with 5%
BSA in TBS-T at RT and then incubated with the primary
antibody at 4uC overnight. The membrane was washed 3610
minutes in TBS-T, before being incubated with the secondary,
HRP-labeled antibody. After extensive washing, the protein was
visualized by ECL.
Figure 1. EFhd2 is dispensable for platelet production. (A) Analysis of EFhd2 expression in Efhd2+/+ and Efhd2-/- platelets by Western blot.
Expression of GPIIIa was used as loading control. (B) Peripheral platelet counts and (C) platelet volume of Efhd2+/+ and Efhd2-/- mice measured with a
blood cell counter are depicted. Results are mean6 SD of 7 mice per group. (D) Determination of the platelet life span in wild-type and Efhd2-/- mice.
Mice were injected with a DyLight 488-conjugated anti-GPIX derivate (0.5 mg/g body weight) to label platelets in vivo. Results are% of fluorescently
labeled platelets at the indicated days after injection as determined by flow cytometry. Values are mean6 SD of 5 mice per group. (E) Determination
of MK numbers per visual field (2946221 mm) in hematoxylin and eosin stained BM sections. Values are mean 6 SD (n = 5).
doi:10.1371/journal.pone.0107139.g001
Table 1. Efhd2-/- mice display normal hematologic parameters.
Genotype Efhd2 WBC6103/mL RBC6106/mL HGB [g/dL] HCT [%]
+/+ 10.7863.78 8.3960.87 14.2860.80 44.2463.51
-/- 12.9563.16 8.2961.40 13.5862.20 42.9867.10
p value n.s. n.s. n.s. n.s
White blood cell count (WBC), red blood cells (RBC), hemoglobin (HGB) and hematocrit (HCT) were determined with a hematologic analyzer (Sysmex) (n = 5 vs. 5, two
independent experiments, n.s. = not significant).
doi:10.1371/journal.pone.0107139.t001
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Platelet adhesion under flow conditions
Heparinized whole blood was perfused over collagen-coated
cover slips as described [32]. Before perfusion, anticoagulated
blood was incubated with DyLight-488-conjugated anti-GPIX
derivative (0.2 mg/mL) at 37uC for 5 minutes. Aggregate
formation was visualized with a Zeiss Axiovert 200 inverted
microscope (40x/0.60 objective). Phase-contrast and fluorescence
pictures were recorded with a CoolSNAP-EZ camera, and
analyzed off-line using Metavue software. Thrombus formation
was analyzed as the mean percentage of the total area covered by
platelets/thrombi in phase contrast images. Mean integrated
fluorescence intensity per mm2 gave an indication about thrombus
volume.
Intracellular Ca2+ measurements
Washed platelets were suspended in Tyrodes-HEPES buffer
without Ca2+, and loaded with fura-2/AM (5 mmol/L) in the
presence of Pluronic F-127 (0.2 mg/mL) for 20 minutes at 37uC.
After labeling, platelets were washed once and resuspended in
Tyrodes-HEPES buffer containing 1 mmol/L Ca2+. Stirred
platelets were activated with the respective agonists and fluores-
cence was measured with an LS 55 fluorimeter (PerkinElmer,
USA). Excitation was alternated between 340 and 380 nm, and
emission was measured at 509 nm. Each measurement was
calibrated using Triton X-100 and EGTA.
Tail bleeding time
Mice were anaesthetized and 1 mm segment of the tail tip was
amputated with a scalpel. Tail bleeding was monitored by gentle
absorption of the blood with filter paper at 20 s intervals without
making contact with the wound site. When no blood was observed
on the paper, bleeding was determined to have ceased. Experi-
ments were stopped after 20 min.
Intravital microscopy of thrombus formation in FeCl3-
injured mesenteric arterioles
Intravital microscopy was performed as previously described
[33]. In brief, injury of mesenteric arterioles was induced by
topical application of 20% FeCl3. Adhesion and aggregation of
fluorescently labeled platelets in arterioles was monitored for
40 min or until complete occlusion occurred (blood flow stopped
for 1 min). Mice were between 4 and 5 weeks of age.
Mechanical injury of the abdominal aorta
The abdominal cavity of anaesthetized mice was opened to
expose the abdominal aorta. An ultrasonic flowprobe (0.5PSB699;
Transonic Systems) was placed around the vessel, and thrombus
formation was induced by a single firm compression with a forceps
upstream of the flowprobe. Blood flow was monitored for 30 min.
Triple anaesthesia
Mice were anesthetized i.p. with a combination of medetomi-
dine/fentanyl/midazolam (0.5/0.05/5 mg kg-1 body weight).
Statistics
Results from at least three independent experiments per group
are presented as mean 6 SD. For statistical analysis between
Table 2. Unaltered expression of platelet glycoproteins in Efhd2-/- mice.
- MFI ± SD Efhd2 +/+ MFI ± SD Efhd2 -/- p value
GPIb 330.6613.4 329.868.3 n.s.
GPVI 41.061.0 39.460.9 n.s.
GPV 242.064.8 242.663.3 n.s.
GPXI 377.465.5 38068.6 n.s.
CD9 968.269.3 969.6617.0 n.s.
aIIbb3 543.6617.9 555.8619.5 n.s.
a2 40.461.1 40.661.1 n.s.
b1 102.465.2 101.662.3 n.s.
CLEC-2 101.8613.5 100.662.6 n.s.
Expression of glycoproteins on the platelet surface was determined by flow cytometry. Diluted whole blood from the indicated mice was incubated with FITC-labeled
antibodies at saturating conditions for 15 minutes at RT, and platelets were analyzed directly. Data are expressed as mean fluorescence intensity 6 SD (n = 4) and are
representative of 3 individual experiments. n.s. = not significant, SD = standard deviation.
doi:10.1371/journal.pone.0107139.t002
Figure 2. Unaltered aggregation response of Efhd2-/- platelets.
Washed platelets from Efhd2+/+ (black line) and Efhd2-/- (gray line) mice
were activated with the indicated agonist concentrations and light
transmission was recorded on a Fibrintimer 4-channel aggregometer.
ADP measurements were performed in prp. Representative aggregation
traces of at least 3 individual experiments are depicted.
doi:10.1371/journal.pone.0107139.g002
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Figure 3. Normal aIIbb3 activation and a-granule release in Efhd2 -/- platelets. Flow cytometric analysis of integrin aIIbb3 activation (A) and
degranulation-dependent P-selectin exposure (B) in response to the indicated agonists in Efhd2+/+ and Efhd2-/- platelets. Results are mean
fluorescence intensities (MFI) 6 SD of 4 mice per group and are representative of 4 individual experiments. CRP: collagen-related peptide, CVX:
convulxin, and RC: rhodocytin.
doi:10.1371/journal.pone.0107139.g003
Figure 4. Normal integrin outside-in signaling in Efhd2 -/- platelets. (A-C) Washed platelets of Efhd2+/+ and Efhd2-/- mice were allowed to
spread on fibrinogen (100 mg/mL) for 30 min after stimulation with 0.01 U/mL thrombin. (A) Statistical evaluation of the percentage of spread
platelets at different spreading stages and (B) representative differential interference contrast (DIC) images of 2 individual experiments. 1: roundish, 2:
only filopodia, 3: filopodia and lamellipodia, 4: fully spread. (C) Visualization of filamentous actin (red) in spread (30 min) Efhd2+/+ and Efhd2-/- platelets
by cofocal microscopy. (D) Clot retraction of prp upon activation with 4 U/mL thrombin in the presence of 20 mmol/L CaCl2 at the indicated time
points (n = 6).
doi:10.1371/journal.pone.0107139.g004
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experimental groups we applied the unpaired two-tailed student’s
t-test. All statistical evaluation was done with OriginPro 8.6G. P-
values,0.05 compared to control were considered statistically
significant (p-value,0.05= *; ,0.01= **; ,0.001= ***).
Results
EFhd2 is expressed in murine platelets but dispensable
for platelet production
To study the role of EFhd2 in platelet physiology, we took
advantage of constitutive EFhd2 knockout mice [19]. Western blot
analysis confirmed the expression of EFhd2 in wild-type (Efhd2+/+)
platelets and the absence of EFhd2 in platelets from Efhd2-/- mice
(Figure 1 A). Analysis of basic blood parameters with a Sysmex cell
counter revealed unaltered white and red blood cell counts as well
as unchanged hemoglobin content of red blood cells and
haematocrit in Efhd2-/- mice compared to wild-type controls
(Table 1). Platelet count, size, and life span, as well as surface
expression levels of prominent glycoprotein receptors were
unaltered compared to the wild-type control (Figure 1 B–D,
Table 2), indicating that megakaryopoiesis and platelet formation
can occur independently of EFhd2. This was corroborated by
normal MK numbers in the bone marrow of the mutant animals
(wild-type: 7.5760.5 MK/visual field, Efhd2-/- 8.661.4 MK/
visual field; Figure 1 E).
Platelet activation and aggregation were unaffected by
loss of EFhd2
To study the consequences of EFhd2-deficiency on platelet
function, we performed ex vivo aggregation studies. Efhd2-/-
platelets showed unaltered shape change and aggregated normally
in response to the G protein-coupled receptor (GPCR) agonists
thrombin, ADP and the thromboxane A2 (TxA2) analogue
U46619 as well as after stimulation of the immunoreceptor
tyrosine-based activation motif (ITAM)-coupled receptor glyco-
protein (GP) VI by collagen or CRP (Figure 2). These findings
were confirmed by flow cytometric analysis of integrin aIIbb3
activation (Figure 3 A) and of degranulation-dependent P-selectin
surface exposure (Figure 3 B). Similarly, platelet activation via the
(hem)ITAM-receptor CLEC-2 by the snake venom toxin rhodo-
cytin (RC) was unaltered in Efhd2-/- platelets (Figure 3). These
results demonstrate that EFhd2 is dispensable for platelet
activation by classic agonists.
Efhd2-/- platelets show normal integrin outside-in
signaling
Ligand-occupied integrin aIIbb3 mediates outside-in signaling,
leading to cytoskeletal reorganization and platelet spreading [34].
EFhd2 has been proposed to play a crucial role in these processes
in different cell types [18]. To test this in platelets, Efhd2-/- and
wild-type platelets were allowed to spread on a fibrinogen-coated
surface in the presence of low concentrations of thrombin
(Figure 4 A). Surprisingly, Efhd2-/- and wild-type platelets formed
filopodia and lamellipodia with similar kinetics and after 30
minutes the number of fully spread platelets was comparable
between the two groups (Figure 4 A and B). In line with this,
Efhd2-/- spread platelets displayed normal actin distribution and
content (Figure 4 C). Integrin aIIbb3 outside-in signaling also
regulates clot retraction [35]. Therefore, we induced clot
formation in platelet rich plasma (prp) by addition of a high dose
of thrombin (4 U/ml) and 20 mmol/L CaCl2, and monitored
retraction over time. No differences between wild-type and
Efhd2-/- platelets were observed (Figure 4 D). Together, our data
demonstrate that EFhd2 is not required for the orchestration of
actin rearrangements during integrin aIIbb3-controlled spreading
and clot retraction.
Efhd2-/- platelets show normal Ca2+ mobilization and
slightly increased coagulant activity
Agonist-induced platelet activation leads to an increase in
cytosolic calcium concentrations ([Ca2+]i) through release of Ca
2+
from intracellular stores and Ca2+ entry across plasma membrane
Ca2+ channels [7]. EFhd2 possesses two functional EF hand
domains capable of binding Ca2+ thereby mediating self-
oligomerization and modulating F-actin bundling and cell
spreading [18]. To test whether the lack of EFhd2 affected Ca2+
signaling in platelets, we studied agonist-induced changes in
[Ca2+]i fluorimetrically. Efhd2
-/- platelets displayed normal Ca2+
store release and entry in response to CRP and thrombin (Figure 5
Figure 5. Normal Ca2+-mobilization but slightly increased
procoagulant activity in EFhd2-deficient platelets upon stim-
ulation. (A) Maximal increase of cytosolic Ca2+ concentration ([Ca2+]i)
of Efhd2+/+ (black bars) and Efhd2-/- platelets (gray bars) after activation
with the indicated agonists (thrombin 0.1 U/ml, CRP 4 mg/ml). (B) Flow
cytometric analysis of phosphatidylserine (PS) exposure in response to
the indicated agonists in Efhd2+/+ and Efhd2-/- platelets. Washed
platelets were stained with Annexin-V-DyLight-488 in the presence of
Tyrodes-HEPES buffer containing 3 mmol/L Ca2+. The values represent
the mean fluorescence intensity (MFI) 6 SD for 5 mice per group in 3
independent experiments. Thr: thrombin, CRP: collagen related peptide,
CVX: convulxin, RC: rhodocytin, n.s.: not significant, *p,0.05.
doi:10.1371/journal.pone.0107139.g005
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A) indicating that EFhd2 is dispensable for Ca2+ signaling in
platelets after stimulation with major platelet agonists.
GPVI-stimulated platelets facilitate coagulation by the exposure
of negatively charged phosphatidylserine (PS) on their outer
surface, thereby providing high affinity binding sites for key
coagulation factors [36]. To test a possible role of EFhd2 in the
induction of coagulant activity, washed platelets were stimulated
with different agonists and PS exposure was analyzed. After
stimulation with the combination of CRP/thrombin as well as
high concentrations of rhodocytin the majority of wild-type and
Efhd2-/- platelets exposed PS on their surface (Figure 5 B).
Interestingly, Efhd2-/- platelets displayed a slightly increased PS
exposure in response to CRP which produced only a minor
increase in PS exposure in wild-type platelets (Figure 5 B). These
results revealed that EFhd2 might to a minor extent inhibit ITAM-
induced coagulant activity in platelets.
Unaltered aggregate formation of Efhd2-/- platelets on
collagen under flow
Thrombus formation at sites of vascular injury requires stable
shear-resistant platelet adhesion on the ECM as well as auto- and
paracrine platelet activation by locally released or generated
secondary mediators [37]. To address the effect of EFhd2-
deficiency on these processes, platelet adhesion to collagen was
studied in an ex vivo whole blood perfusion system. When blood
was perfused over immobilized collagen at a shear rate of 1000 s21
or 1700 s21 wild-type and Efhd2-/- platelets rapidly adhered to the
collagen surface with comparable kinetics and recruited additional
platelets from the blood stream resulting in the formation of stable
three-dimensional thrombi (Figure 6). As a result, both the surface
area covered by platelets (1000 s21: Efhd2+/+: 44.8614.4% vs.
Efhd2-/-: 39.969.8%; 1700 s21: Efhd2+/+: 34.2610.2% vs.
Efhd2-/-: 33.765.6%; Figure 6 A and B, left) and the thrombus
volume (1000 s21: Efhd2+/+: 3.261.3 vs. Efhd2-/-: 3.761.7;
1700 s21: Efhd2+/+: 3.362.3 vs. Efhd2-/-: 4.461.9 Figure 6 A
and B, right) at the end of the perfusion period were similar in
wild-type and Efhd2-/- platelets. These results demonstrate that
EFhd2 is not essential for platelet adhesion and aggregate
formation on collagen under flow.
Normal hemostasis and arterial thrombus formation in
Efhd2-/- mice
To study the effect of EFhd2-deficiency on hemostasis, tail
bleeding times were determined (Figure 7 A). Efhd2-/- and wild-
type mice exhibited comparable bleeding times (mean bleeding
time: Efhd2+/+: 5276229 s vs. Efhd2-/-: 5426189 s) suggesting
that hemostasis is not affected in the absence of EFhd2.
To examine whether EFhd2-deficiency affected thrombus
formation in vivo, we subjected the mice to a thrombosis model
where the abdominal aorta is mechanically injured and blood flow
is monitored with an ultrasonic perivascular Doppler flow probe.
In line with our in vitro results, wild-type and Efhd2-/- mice
formed occlusive thrombi with similar kinetics (mean occlusion
time: Efhd2+/+: 3156182 s vs. Efhd2-/-: 2796144 s; Figure 7 B).
Similar results were obtained in a model of FeCl3-induced injury
of mesenteric arterioles. The appearance of first thrombi.10 mm
(Efhd2+/+: 7.5861.87 min vs. Efhd2-/-: 8.3661.70 min; Figure 7
C, left) as well as the time to vessel occlusion (Efhd2+/+:
Figure 6. Normal adhesion and aggregate formation of Efhd2-/- platelets on collagen under flow. Whole blood from Efhd2+/+ or Efhd2-/-
mice was perfused over a collagen-coated surface (0.2 mg/mL) at a shear rate of 1000 s21 (A) or 1700 s21 (B). Representative images of aggregate
formation on collagen after 4 minutes of perfusion time. Mean surface coverage (left) and relative thrombus volume expressed as integrated
fluorescence intensity (IFI) (right) 6 SD of 5 Efhd2+/+ and 5 Efhd2-/- mice.
doi:10.1371/journal.pone.0107139.g006
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16.8962.23 min vs. Efhd2-/-: 15.5162.75 min; Figure 7 C,
middle) was comparable between wild-type and mutant mice.
Representative images of thrombus formation in this model are
shown in Figure 7C, right. These results indicate that EFhd2 is not
required for hemostatic and thrombotic function of platelets in
vivo.
Normal expression of cytoskeletal and signaling proteins
EFhd1 is a close homologue of EFhd2 and exhibits a high
degree of sequence identity at the protein level (64.58%) [15]. To
test a possible compensatory up-regulation of EFhd1 expression in
Efhd2-/- platelets, we performed Western blot analysis and found
the protein to be absent in both wild-type and Efhd2-/- platelets
(Figure 8 A). In addition, actin and tubulin content and the
expression of Rac1 and mDia1 were unaltered in Efhd2-/- platelets
(Figure 8 A). Furthermore, we detected comparable levels of
phosphorylated (inactive) cofilin in mutant and wild-type platelets
and did not observe compensatory basal activation of Syk or
PAK1/2 (Figure 8 B) in resting platelets.
Figure 7. Unaltered thrombotic and hemostatic function in EFhd2-deficient mice. (A) Tail bleeding times of Efhd2+/+ and Efhd2-/- mice. Each
symbol represents one animal. (B) Time to stable vessel occlusion of Efhd2+/+ and Efhd2-/- mice. The abdominal aorta was injured by firm compression
with a forceps and blood flow was monitored for 30 min. Each symbol represents one animal. (C) Appearance of first thrombi (left) and time to
occlusion (middle). Small mesenteric arterioles were injured by topical application of FeCl3 and thrombus formation of fluorescently labeled platelets
was monitored using intravital microscopy. Each symbol represents one mesenteric arteriole. The horizontal dotted line indicates the mean time to
vessel occlusion. Representative images of the FeCl3-induced injury model of mesenteric arterioles in Efhd2
+/+ and Efhd2-/- mice, asterisk indicates
stable occlusion of the vessel (right).
doi:10.1371/journal.pone.0107139.g007
Figure 8. Normal expression levels of specific proteins in
EFhd2-deficient platelets. (A) Analysis of EFhd1, Rac1, mDia1, actin
and tubulin expression in Efhd2+/+ and Efhd2-/- platelets by Western
blot. (B) Analysis of phospho-cofilin, phospho-Syk, and phospho-PAK1/2
expression in Efhd2+/+ and Efhd2-/- platelets by Western blot. Staining of
the respective non-phosphorylated proteins served as loading controls.
doi:10.1371/journal.pone.0107139.g008
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Discussion
In this study, constitutive knockout mice for EFhd2 were used to
assess the role of this Ca2+- binding cytoskeletal adaptor protein for
platelet function in vitro and in vivo. We show that activation
responses are comparable between EFhd2-deficient and wild-type
platelets in vitro and that hemostasis and arterial thrombosis are
unaltered in vivo, indicating that EFhd2 is not required for
hemostatic platelet function in mice.
Rearrangements of the platelet actin and tubulin cytoskeleton
are essential for platelet production, but also for proper platelet
function and hemostasis. These processes are regulated by a
variety of cytoskeletal proteins including Rho GTPases [38–41]
and actin-binding proteins, such as cofillin and ADF [39].
Interestingly, EFhd2 was described in different cell types as an
F-actin binding protein, which regulates actin remodeling in a
Ca2+- and Rac1-dependent manner, as well as cell spreading and
the accessibility of F-actin to cofilin [18,23–26]. However, due to
the lack of an appropriate animal model, these studies were so far
only performed in cell culture systems with the help of
recombinant EFhd2 proteins carrying various mutations or gene
silencing. In contrast, we have recently demonstrated that EFhd2
is not involved in the regulation of the total F-actin content in B
cells [19]. In line with this, we here show that Efhd2-/- platelets
exhibit an unaltered F-actin content (Figure 4 C and 8 A)
associated with unaltered spreading (Figure 4 A–C) and clot
retraction (Figure 4 D), demonstrating that EFhd2 is not essential
for orchestrating actin rearrangements in murine platelets.
Importantly, the close homolog EFhd1 was not compensatory
up-regulated in EFhd2-deficient platelets (Figure 8 A). Further-
more, neither Rac1 expression nor cofilin (de-)phosphorylation
were altered in resting Efhd2-/- platelets compared to wild-type
control (Figure 8 A and B) and also tubulin and the RhoA effector
mDia1, which is known to regulate actin polymerization and
microtubule stabilization, were normally expressed, indicating that
EFhd2-deficiency has no major impact on the expression and
activity of important cytoskeleton regulating proteins. Additional-
ly, we found also normal platelet count, size, glycoprotein
expression, platelet life span and MK number in the bone marrow
(Figure 1), suggesting that EFhd2 is dispensable for platelet
production in vivo.
Besides the ability of EFhd2 to interact with actin or actin-
binding molecules, EFhd2 contains two functional EF-hand
domains capable of binding Ca2+ [17]. Furthermore, EFhd2 is
involved in B cell receptor-mediated apoptosis by amplifying Ca2+
influx through positive regulation of Syk [16]. However, we found
normal platelet activation downstream of GPCRs as well as
(hem)ITAM-bearing receptors (Figure 2 and 3) and unaltered
Ca2+-mobilization after platelet stimulation (Figure 5 A), demon-
strating that EFhd2 is not required for these processes.
Additionally, expression of Syk and PAK1/2/3, as well as their
phosphorylation were unaltered in Efhd2-/- platelets under resting
conditions compared to wild-type control (Figure 8 B). Neverthe-
less, coagulant activity was slightly but significantly increased
specifically after GPVI stimulation (Figure 5 B). The physiological
significance of this difference is unclear, but may imply that EFhd2
negatively regulates GPVI-triggered procoagulant activity. How-
ever, we found unaltered platelet adhesion and aggregate
formation under flow on collagen in the absence of EFhd2
(Figure 6), and, therefore, do not support this conclusion. In line
with these in vitro findings, our in vivo analysis of EFhd2-deficient
mice demonstrated normal hemostasis and arterial thrombosis
(Figure 7), indicating that EFhd2 is dispensable for platelet
function in models of hemostasis and thrombosis.
Taken together, our results demonstrate that EFhd2 is not
required for proper platelet production and function of the cells in
hemostasis and thrombosis in mice. Most likely, redundancies with
other Ca2+- and actin-binding proteins can compensate for the loss
of EFhd2. Given that EFhd2 expression in platelets is up-regulated
during sepsis and has been associated with neurodegenerative
processes, it is tempting to speculate that EFhd2 may be relevant
for platelet functions other than clot formation such as inflamma-
tion, immune defense or wound healing. This will require further
investigation and we believe that EFhd2-deficient mice will be a
valuable tool for these studies.
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